Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

rad data australia pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; purified talc; magnesium stearate - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; magnesium stearate; purified talc; lactose monohydrate; colloidal anhydrous silica - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: purified talc; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; calcium hydrogen phosphate dihydrate; ammonio methacrylate copolymer - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - melatonin - oral solution - 1.2mg/1ml

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - melatonin - oral suspension - 1.2mg/1ml

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; lactose monohydrate; purified talc; ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - melatonin, quantity: 2 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; povidone; maltodextrin; magnesium stearate; titanium dioxide; indigo carmine; gelatin - adult,short-term treatment of jet lag in adults aged 18 and over.,paediatric,sleep disorders in children and adolescents aged 6 to 18 with neurodevelopmental disorders including autism spectrum disorder (asd) and attention deficit hyperactivity disorder (adhd), where sleep hygiene measures have been insufficient.

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vemedia manufacturing b.v. - melatonin 3 mg - tablet - 3 mg - melatonin 3 mg - melatonin

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vemedia manufacturing b.v. - melatonin 5 mg - tablet - 5 mg - melatonin 5 mg - melatonin

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk - melatonin - modified-release tablet - 2mg